MedTrace Logo

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

NCT04948788 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2021-09-28

No results posted yet for this study

Summary

The study is evaluating the efficacy, and safety of SHR1459 combined with YY-20394 for Recurrent and refractory B-cell non-Hodgkin's lymphoma in adults.

Conditions

  • Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG

SHR1459 ；YY-20394

SHR1459 plus YY-20394

DRUG

SHR1459 ；YY-20394

SHR1459 plus YY-20394

DRUG

Gemcitabine-Oxaliplatin

Gemcitabine-Oxaliplatin

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-31
Primary Completion
2023-04-30
Completion
2023-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04948788 on ClinicalTrials.gov